Schneider seems to be keen on taking Arctic Wolf public, and though he declines to discuss specifics on timing, he says he’s watching market conditions closely.
/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.